Farmas USA

hoy hay opciones en muchas farmss, los cierres ya estan escritos

acabo de ver una new muy posiitiva pero erronea de NVAX en stocktwit, CASI ME DA UN JAMACUCO JODER

Cabrón, que me has hecho ir a mirarla. ¿Y no será información privilegiada? XD

ojala, pero parece ser que la new se referia a Novartis ( NVS )

ATHX

Del Bastardo, y tiene razón. Yo sigo creyendo en el potencial de sus células, pero los ensayos como ya dije en su día estaban mal hechos. Tendrán que volver a empezar y ahora toca dilución.

Let's unpack this: For starters, stroke is an acute illness requiring immediate medical intervention. A clinically meaningful outcome for stroke victims is improvement or recovery measured days or weeks after the stroke, not one year later.

Athersys used a "global test analysis" encompassing three different stroke-recovery measures -- the modified Rankin Scale (mRS), the NIH Stroke Scale and the Barthel Index -- to assess MultiStem's ability to improve recovery from a stroke after 90 days. On this measure, the study's primary efficacy endpoint, MultiStem was no different than placebo.

Secondarily, Athersys looked at each of the three stroke-recovery measures individually to detect a difference between MultiStem and placebo. The company found no difference.

Athersys defines "complete or nearly full recovery" as patients achieving an "excellent outcome," which is just a dumbed-down revision of the more stringent "global test analysis" measure used as the primary endpoint in the study. [The primary endpoint which MultiStem couldn't achieve last April].

After 90 days of follow-up -- the only time point that matters -- MultiStem also failed to demonstrate an improvement over placebo using the "excellent outcome" definition of stroke recovery. This just underscores its weakness: The stem cell therapy couldn't even muster a win over placebo using a remedial definition of stroke recovery.

http://www.thestreet.com/story/13464490/1/should-you-buy-into-athersys-rsquo-latest-spin-on-failed-stroke-therapy.html?puc=yahoo&cm_ven=YAHOO

ADXS

Junta de accionistas el 10 de marzo

- Election of directors

- To approve an amendment to our Amended and Restated Certificate of Incorporation to increase our authorized shares of common stock by 20,000,000 shares from 45,000,000 to 65,000,000.

- To approve an amendment to our 2015 Incentive Plan to authorize an additional 1,000,000 shares thereunder.

- Consider and approve an advisory (non-binding) resolution regarding the compensation of our named executive officers.

- To ratify the selection of Marcum, LLP as our independent registered public accountants for the fiscal year ending October 31, 2016, which we refer to as fiscal 2016.

NVAX

Bueno, di por hecho lo que todos sabemos, que framus es el Rey de Reyes, y en la comparativa, todos mindundis, jajaja.

calla, calla ... que soy el rey pero palmando pasta ...